{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-050739","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.994173+00:00","generated_at":"2026-06-05T08:29:42.259163+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MiMedx Q4 net sales $87M (+17% YoY); FY $321M (+20%); guides 2024 low double-digit growth","bullets":["Net sales Q4 $87M, FY $321M, up 17% and 20% YoY respectively.","GAAP net income Q4 $53M (incl. $40M one-time tax benefit), FY $58M.","Adjusted EBITDA Q4 $21M, margin 24%.","2024 guidance: low double-digit net sales growth, adjusted EBITDA margin >20%.","Launched EPIEFFECT wound care product; completed debt refinancing Jan 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-050739","json":"https://secwatch.observer/filing/0001193125-24-050739.json","markdown":"https://secwatch.observer/filing/0001193125-24-050739.md","text":"https://secwatch.observer/filing/0001193125-24-050739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/0001193125-24-050739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/d801521d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:29:42.259163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a11064b65e6ff38ab6b58856c14ae88ce47a5ad1","claim":"MIMEDX GROUP, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Fourth quarter and full year 2023 net sales of $87 million and $321 million, net income GAAP Net Income for the fourth quarter and full year 2023 of $53 million and $58 million, respectively.. Guidance reaffirmed.","evidence_excerpt":"On February 28, 2024, MiMedx Group, Inc. (the “ Company ”), issued a press release (the “ Earnings Press Release ”) announcing its results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/0001193125-24-050739-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Fourth quarter and full year 2023 net sales of $87 million and $321 million"},{"label":"Net income","value":"GAAP Net Income for the fourth quarter and full year 2023 of $53 million and $58 million, respectively."},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}